Acute stroke therapy: Perspectives on current, future treatments

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Stroke is the third leading cause of death in the United States, yet no acute stroke treatment was available until tissue plasminogen activator (t- PA) was approved for this indication in 1996. This intravenously administered thrombolytic agent is the first to show improved recovery in stroke patients. An associated risk of intracranial hemorrhage (ICH), however, requires careful selection of patients for t-PA therapy. Other intravenously and intra-arterially administered thrombolytics are being investigated for use in stroke, while trials of the thrombolytic streptokinase have been aborted due to high rates of ICH. Stroke therapies categorized as neuroprotective agents are also being studied in clinical trials. These drugs work to preserve cells in the penumbra region of the infarct that have not yet been irreversibly damaged. This article reviews the clinical use of t-PA and the status of investigational acute stroke treatments.

Original languageEnglish (US)
Pages (from-to)1040-1055
Number of pages16
JournalFormulary
Volume32
Issue number10
StatePublished - 1997

Fingerprint

Stroke
Intracranial Hemorrhages
Therapeutics
Streptokinase
Fibrinolytic Agents
Neuroprotective Agents
Tissue Plasminogen Activator
Patient Selection
Cause of Death
Clinical Trials
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Acute stroke therapy : Perspectives on current, future treatments. / Lutsep, Helmi; Clark, Wayne.

In: Formulary, Vol. 32, No. 10, 1997, p. 1040-1055.

Research output: Contribution to journalArticle

@article{751579116a1c4142ac4ace13048e07f0,
title = "Acute stroke therapy: Perspectives on current, future treatments",
abstract = "Stroke is the third leading cause of death in the United States, yet no acute stroke treatment was available until tissue plasminogen activator (t- PA) was approved for this indication in 1996. This intravenously administered thrombolytic agent is the first to show improved recovery in stroke patients. An associated risk of intracranial hemorrhage (ICH), however, requires careful selection of patients for t-PA therapy. Other intravenously and intra-arterially administered thrombolytics are being investigated for use in stroke, while trials of the thrombolytic streptokinase have been aborted due to high rates of ICH. Stroke therapies categorized as neuroprotective agents are also being studied in clinical trials. These drugs work to preserve cells in the penumbra region of the infarct that have not yet been irreversibly damaged. This article reviews the clinical use of t-PA and the status of investigational acute stroke treatments.",
author = "Helmi Lutsep and Wayne Clark",
year = "1997",
language = "English (US)",
volume = "32",
pages = "1040--1055",
journal = "Hospital Formulary",
issn = "0098-6909",
publisher = "Advanstar Communications",
number = "10",

}

TY - JOUR

T1 - Acute stroke therapy

T2 - Perspectives on current, future treatments

AU - Lutsep, Helmi

AU - Clark, Wayne

PY - 1997

Y1 - 1997

N2 - Stroke is the third leading cause of death in the United States, yet no acute stroke treatment was available until tissue plasminogen activator (t- PA) was approved for this indication in 1996. This intravenously administered thrombolytic agent is the first to show improved recovery in stroke patients. An associated risk of intracranial hemorrhage (ICH), however, requires careful selection of patients for t-PA therapy. Other intravenously and intra-arterially administered thrombolytics are being investigated for use in stroke, while trials of the thrombolytic streptokinase have been aborted due to high rates of ICH. Stroke therapies categorized as neuroprotective agents are also being studied in clinical trials. These drugs work to preserve cells in the penumbra region of the infarct that have not yet been irreversibly damaged. This article reviews the clinical use of t-PA and the status of investigational acute stroke treatments.

AB - Stroke is the third leading cause of death in the United States, yet no acute stroke treatment was available until tissue plasminogen activator (t- PA) was approved for this indication in 1996. This intravenously administered thrombolytic agent is the first to show improved recovery in stroke patients. An associated risk of intracranial hemorrhage (ICH), however, requires careful selection of patients for t-PA therapy. Other intravenously and intra-arterially administered thrombolytics are being investigated for use in stroke, while trials of the thrombolytic streptokinase have been aborted due to high rates of ICH. Stroke therapies categorized as neuroprotective agents are also being studied in clinical trials. These drugs work to preserve cells in the penumbra region of the infarct that have not yet been irreversibly damaged. This article reviews the clinical use of t-PA and the status of investigational acute stroke treatments.

UR - http://www.scopus.com/inward/record.url?scp=0030680276&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030680276&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:0030680276

VL - 32

SP - 1040

EP - 1055

JO - Hospital Formulary

JF - Hospital Formulary

SN - 0098-6909

IS - 10

ER -